LEMAITRE VASCULAR INC — Director's Dealing 2020

Dec 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEMAITRE VASCULAR INC (LMAT)
CIK: 0001158895
Period of Report: 2020-12-02

Reporting Person: LeMaitre George W (Director, Chairman and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-02	Common Stock	A	4861	$37.29	Acquired	2784681	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-02	Stock Option (Right to Buy)	$37.29	A	39182	Acquired	2027-12-02	Common Stock (39182)	Direct
2020-12-03	Dividend Equivalent Rights	$	A	6	Acquired		Common Stock (6)	Direct
2020-12-03	Dividend Equivalent Rights	$	A	9	Acquired		Common Stock (9)	Direct
2020-12-03	Dividend Equivalent Rights	$	A	16	Acquired		Common Stock (16)	Direct
2020-12-03	Dividend Equivalent Rights	$	A	13	Acquired		Common Stock (13)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect

Footnotes

F1: Represents a restricted stock unit award that vests on a time-based schedule as follows: 20% of the award vests on the anniversary of the grant date listed in the table, with the balance vesting in equal annual installments over the remaining four years. This award includes a provision for the withholding of shares by the Issuer to pay the withholding taxes due on each vesting date.

F2: These shares are owned by LeMaitre Family LLC. A trust for the benefit of the Reporting Person holds a 20% membership interest in LeMaitre Family LLC. LeMaitre Family LLC is 100% owned by Christopher Lynch, as trustee for various trusts formed for the benefit of the children of George D. LeMaitre, the Issuer's founder, and Cornelia W. LeMaitre. LeMaitre Family LLC currently holds 50,000 shares of the Issuer's Common Stock. The Reporting Person disclaims ownership of such securities except to the extent of his pecuniary interest therein, if any, and the reporting herein of such securities shall not be construed as an admission of beneficial ownership thereof for the purposes of Section 16 or for any other purpose.

F3: The exercise price of this option to the extent it is an incentive stock option is $41.02 per share, and the exercise price of this option to the extent it is a nonqualified stock option is $37.29 per share.

F4: This option is exercisable and vests over a five-year period at a rate of 20% on the first anniversary of the date listed in the table, and the balance vests in equal annual installments over the remaining four years, with the final vesting occurring on the 11th month after the fourth anniversary.

F5: The expiration date of this option to the extent it is an incentive stock option is 12/2/2025, and the expiration date of this option to the extent it is a nonqualified stock option is 12/2/2027.

F6: These dividend equivalent rights accrued on a restricted stock unit award granted on 7/25/2016 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

F7: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/22/2017 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

F8: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/19/2018 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

F9: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/20/2019 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.